Caribou Biosciences (NASDAQ:CRBU) Cut to Market Perform at Leerink Partners

Leerink Partners cut shares of Caribou Biosciences (NASDAQ:CRBU) from an outperform rating to a market perform rating in a research report released on Wednesday, Marketbeat Ratings reports. The brokerage currently has $1.00 price target on the stock.

Other equities research analysts have also issued research reports about the company. Royal Bank Of Canada lowered Caribou Biosciences from an “outperform” rating to a “sector perform” rating and set a $1.00 price target on the stock. in a research note on Wednesday. Brookline Capital Markets cut shares of Caribou Biosciences from a “buy” rating to a “hold” rating in a research note on Wednesday. Wall Street Zen downgraded shares of Caribou Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, September 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Caribou Biosciences in a research report on Friday, July 17th. Finally, Bank of America cut their price target on shares of Caribou Biosciences from $6.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $5.50.

Caribou Biosciences Stock Down 4.4%

Shares of NASDAQ:CRBU opened at $0.46 on Wednesday. The business’s 50 day moving average is $1.41 and its 200 day moving average is $1.73. The stock has a market cap of $49.34 million, a P/E ratio of -0.43 and a beta of 2.31. Caribou Biosciences has a 52-week low of $0.44 and a 52-week high of $3.54.

Caribou Biosciences (NASDAQ:CRBU) last issued its earnings results on Thursday, August 13th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.08. The business had revenue of $1.50 million during the quarter, compared to analyst estimates of $2.28 million. Caribou Biosciences had a negative return on equity of 89.11% and a negative net margin of 1,030.42%. On average, sell-side analysts anticipate that Caribou Biosciences will post -1.17 EPS for the current fiscal year.

Institutional Investors Weigh In On Caribou Biosciences

Large investors have recently bought and sold shares of the stock. BlackRock Inc. purchased a new stake in Caribou Biosciences during the 2nd quarter worth $13,756,000. Renaissance Technologies LLC increased its position in shares of Caribou Biosciences by 58.0% during the first quarter. Renaissance Technologies LLC now owns 2,590,497 shares of the company’s stock worth $4,922,000 after acquiring an additional 950,640 shares during the last quarter. Bank of America Corp DE acquired a new stake in Caribou Biosciences in the second quarter valued at $2,483,000. GSA Capital Partners LLP acquired a new position in shares of Caribou Biosciences in the 2nd quarter worth approximately $816,000. Finally, Green Alpha Advisors LLC bought a new stake in shares of Caribou Biosciences in the 2nd quarter valued at approximately $641,000. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Caribou Biosciences News Roundup

Here are the key news stories impacting Caribou Biosciences this week:

• Positive Sentiment: Leerink Partners set a $1.00 price target, substantially above the recent trading level, suggesting potential upside if Caribou’s clinical and business outlook improves. However, the firm simultaneously downgraded the stock to “Market Perform.” Leerink Partners Downgrades Caribou Biosciences to Market Perform
• Neutral Sentiment: HC Wainwright downgraded Caribou from “Buy” to “Neutral” and issued forecasts for continued losses through 2027: $(0.11) EPS in the first quarter, $(0.08) in the second, $(0.07) in the third and $(0.05) in the fourth. The estimates imply gradual improvement but no near-term profitability. HC Wainwright Downgrades Caribou Biosciences to Neutral
• Neutral Sentiment: Reported short interest totaled zero shares as of October 9, producing a zero-day days-to-cover ratio. This indicates no measurable short-position overhang in the reported data, although the figure may reflect a reporting anomaly rather than a meaningful change in investor positioning.
• Negative Sentiment: Brookline Capital Markets also downgraded Caribou to “Hold,” adding to the recent wave of more cautious analyst opinions. Brookline Capital Markets Downgrades Caribou Biosciences to Hold
• Negative Sentiment: A MedCity News report described Caribou’s off-the-shelf cell-therapy effort as reaching the “end of the road,” raising concerns about the company’s pipeline, future catalysts and ability to create shareholder value. Caribou Bio’s Journey With Off-the-Shelf Cell Therapy Reaches the End of the Road

About Caribou Biosciences

Caribou Biosciences, Inc is a clinical-stage biotechnology company developing genome-edited cell therapies for cancer and other serious diseases. The company uses its proprietary CRISPR-based chRDNA genome-editing platform to engineer immune cells, with an emphasis on allogeneic, or “off-the-shelf,” CAR-T therapies designed to target tumors without requiring cells to be collected from each individual patient.

Caribou’s research and development programs have focused primarily on hematologic malignancies, including investigational CAR-T candidates directed at targets such as CD19 and BCMA.